Several upcoming clinical trials are designed to explore the therapeutic benefit of compounds that inhibit NRF2 in advanced cancer patients harboring mutations in NFE2L2 or KEAP1 (ClinicalTrials.gov, NCT02417701; ClinicalTrials.gov, NCT04267913; ClinicalTrials.gov, NCT03872427). The gene discussed is KEAP1; the disease is cancer.